Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia

Cytometry Part B - Clinical Cytometry

Volumn 82 B, Issue 5, 2012, Pages 283-294

  Kim, Hyun Pyo ^a   Bernard, Lea ^a   Berkowitz, Jonathan ^b   Nitta, Janet ^a   Hogge, Donna E ^a,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ABC transporters; acute myeloid leukemia; drug resistance; mitoxantrone efflux assay; pretreatment assessment

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CD19 ANTIGEN; CD38 ANTIGEN; CPX 351; CPX351; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; UNCLASSIFIED DRUG; VALSPODAR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CD3+ T LYMPHOCYTE; CD34 SELECTION; CELL POPULATION; CYTOGENETICS; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 85027930455     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21028     Document Type: Article

References (61)

1. Rubnitz JE, Gibson B, Smith FO,. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010; 24: 35-63.
2. Robak T, Wierzbowska A,. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31: 2349-2370.
3. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, et al. Treatment of acute myelocytic leukemia: A study by cancer and leukemia group B. Blood 1981; 58: 1203-1212.
4. Lowenberg B,. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 65-75.
5. Stone RM,. Prognostic factors in AML in relation to (ab)normal karyotype. Best Pract Res Clin Haematol 2009; 22: 523-528.
6. Damiani D, Tiribelli M, Raspadori D, Michelutti A, Gozzetti A, Calistri E, Candoni A, Chiarvesio A, Lenoci M, Russo D, Fanin R,. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematol Oncol 2007; 25: 38-43.
7. Nimer SD,. Is it important to decipher the heterogeneity of "normal karyotype AML"? Best Pract Res Clin Haematol 2008; 21: 43-52.
8. NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. National Comprehensive Cancer Network. October 18, 2010; 2. Available at: www.nccn.org.
9. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
10. Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S, Nibourel O, Pautas C, Reman O, Thomas X, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009; 113: 5090-5093.
11. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K,. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633.
12. Ohta M,. Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly. Geriatr Gerontol Int 2009; 9: 115-123.
13. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116: 4422-4429.
14. Laupeze B, Amiot L, Drenou B, Bernard M, Branger B, Grosset JM, Lamy T, Fauchet R, Fardel O,. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002; 116: 834-838.
15. Kim DH, Lee NY, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB,. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia. Leuk Lymphoma 2006; 47: 461-467.
16. Malagola M, Baccarani M, Russo D,. Leukemia and multi-drug resistance: Too many mechanisms of drug resistance or too many doctors resistant? Leuk Lymphoma 2009; 50: 1058-1060.
17. Marie JP,. Drug resistance in hematologic malignancies. Curr Opin Oncol 2001; 13: 463-469.
18. Leonard GD, Fojo T, Bates SE,. The role of ABC transporters in clinical practice. Oncologist 2003; 8: 411-424.
19. Eckford PD, Sharom FJ,. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009; 109: 2989-3011.
20. Ozben T,. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006; 580: 2903-2909.
21. Dean M, Rzhetsky A, Allikmets R,. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-1166.
22. Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A, Cavallin M, Fanin R,. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006; 91: 825-828.
23. Norgaard JM, Olesen LH, Hokland P,. Changing picture of cellular drug resistance in human leukemia. Crit Rev Oncol Hematol 2004; 50: 39-49.
24. Fisher GA, Sikic BI,. Drug resistance in clinical oncology and hematology. Introduction. Hematol Oncol Clin North Am 1995; 9: xi-xii.
25. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papa G,. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87: 1997-2004.
26. Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA,. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103: 1083-1091.
27. Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dorken B, Ludwig WD,. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711-721.
28. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A,. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002; 16: 1443-1447.
29. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224-1232.
30. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol 2004; 22: 1078-1086.
31. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP,. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002; 100: 4594-4601.
32. Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R,. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res 1997; 3: 1419-1425.
33. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 1996; 56: 3010-3020.
34. Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippe J,. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 2006; 42: 295-309.
35. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-736.
36. Raaijmakers MH,. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 2007; 21: 2094-2102.
37. Ho MM, Hogge DE, Ling V,. MDR1 and BCRP1 expression in leukemic progenitors predicts chemotherapy response in acute myeloid leukemia. Exp Hematol 2008; 36: 433-442.
38. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008.
39. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
40. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
41. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
42. Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, et al. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose Etoposide and Cyclophosphamide. Biol Blood Marrow Transplant 2006; 12: 480-489.
43. Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheper RJ, Scheffer GL, de Witte TJ, Raymakers RA,. Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia. Clin Cancer Res 2005; 11: 2436-2444.
44. Raaijmakers MH, de Grouw EP, van der Reijden BA, de Witte TJ, Jansen JH, Raymakers RA,. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res 2006; 12: 3452-3458.
45. Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE,. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol 2011; 39: 741-750.
46. Knaust E, Porwit-MacDonald A, Gruber A, Xu D, Peterson C,. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin. Haematologica 2000; 85: 124-132.
47. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E,. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007; 62: 214-226.
48. Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R,. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8: 974-977.
49. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP,. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488.
50. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O,. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004; 10: 7896-7902.
51. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, Legrand O,. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005; 11: 7764-7772.
52. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, Vellenga E, Ossenkoppele GJ, Lowenberg B, Sonneveld P,. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 2007; 86: 329-337.
53. Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheffer G, Scheper RJ, de Witte TJ, Raymakers RA,. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. Leuk Res 2005; 29: 1455-1458.
54. de Figueiredo-Pontes LL, Pintao MC, Oliveira LC, Dalmazzo LF, Jacomo RH, Garcia AB, Falcão RP, Rego EM,. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry Part B Clin Cytom 2008; 74B: 163-168.
55. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH,. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59: 4237-4241.
56. Marie JP, Legrand O, Perrot JY, Chevillard S, Huet S, Robert J,. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations. Semin Hematol 1997; 34: 63-71.
57. Ailles LE, Gerhard B, Kawagoe H, Hogge DE,. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761-1772.
58. Guan Y, Gerhard B, Hogge DE,. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 3142-3149.
59. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH,. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85: 186-193.
60. Abd El-Ghaffar HA, Aladle DA, Farahat SE, Abd El-Hady N,. P-glycoprotein (P-170) expression in acute leukemias. Hematology 2006; 11: 35-41.
61. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B, Pieters R, Sonneveld P,. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002; 16: 833-839.